A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)

Summary

This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy. It will enroll approximately 150 participants at up to 50 sites globally. The study consists of two parts, a 26 week placebo controlled treatment period (Part A) followed by a 36 month extension period (Part B).

Timeline

Start

2025-06-30

Primary completion

2027-06-30

Completion

2027-06-30

Drugs

Indications